Spark Therapeutics' $4.8B deal confirmed as biggest-ever VC-backed exit in Philly - Technical.ly Philly

Business

Mar. 1, 2019 1:21 pm

Spark Therapeutics’ $4.8B deal confirmed as biggest-ever VC-backed exit in Philly

Quick update on this week's news: The University City life sciences company's acquisition by Swiss pharma giant Roche is the biggest acquisition ever of a VC-backed company within city limits, per PitchBook and PACT.

Founded in 2013, the UCity company announced its acquisition this week.

(Courtesy photo)

The eye-popping $4.8 billion sticker price on Spark Therapeutics’ acquisition deal with Roche announced on Monday is shaping up to be the largest exit ever within city limits for a venture-backed company, according to data from financial data provider PitchBook and the Philadelphia Alliance for Capital and Technologies (PACT).

“Filtering down to just Philadelphia proper does reveal that Spark Therapeutics, once the deal closes, will be the biggest exit ever for Philly-based venture-backed exits,” the company said in an email, citing data from an upcoming report.

According to the Seattle-based company’s data, the current holder of the largest Philly-proper exit title goes to Avid Radiopharmaceuticals, which in 2010 announced its acquisition by Lilly in a deal valued at up to $800 million.

Founded in 2013, Spark is a publicly traded spinout of Children’s Hospital of Philadelphia (CHOP), which invested $33 million in the company. The Philadelphia Inquirer reports that CHOP stands to reap a total return of $430 million for its minority stake in Spark Therapeutics.

As part of the acquisition deal, the company will remain based out of 3711 Market St., and continue to do business as a standalone Roche company.

“This transaction demonstrates the enormous value that global biotech companies like Roche see in gene therapy, a field in which Philadelphia is the unquestioned leader,” said Saul Behar, senior VP of  advancement and strategic initiatives at the University City Science Center, the West Philly research park where Spark began and grew its operations. “[This] further validates Greater Philadelphia’s status as a biotech hub with a very bright future.”

Spark CEO Jeff Marrazzo said the deep pool of resources from Roche, the company plans to “accelerate the development of more gene therapies for more patients for more diseases and further expedite our vision of a world where no life is limited by genetic disease.”

Advertisement

-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Why this Radnor-based VC firm thinks impact investing is on the rise

Philly startups need more early-stage investments to compete

Carisma Therapeutics raised nearly $60M in Series A funding. Now what?

SPONSORED

Philly

Meet these 10 hiring companies at Super Meetup

Philadelphia

Perpay

UX Designer

Apply Now
Chesterbrook, PA

Deacom

Inside Sales Representative

Apply Now
Horsham, PA

Penn Mutual

Product Owner/Business Transformation Specialist

Apply Now

A Center City biotech company is using an algorithm to help patients with memory loss

PA Biotech Center just announced a $50M investment fund and accelerator

Philly will host an inaugural pharma conference next month

SPONSORED

Philly

Verizon is looking for the brightest ideas on how to use its 5G technology

Center City

Inspire

Member Experience Specialist

Apply Now
Philadelphia, PA

Perpay

Frontend Engineer

Apply Now

Sign-up for daily news updates from Technical.ly Philadelphia

Do NOT follow this link or you will be banned from the site!